Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01604772 · OUTCOME

Overall Survival

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma · Source last updated 2019-05-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Time of study entry to death due to any cause, assessed up to 3 years from registration

What was measured

Overall Survival is defined as the time from registration to death. The distribution of survival will be estimated using the method of Kaplan-MeierEstimated using Kaplan-Meier methodology.

Analysis population: Two patients were not eligible for this endpoint.

Groups in this outcome

Treatment (Akt Inhibitor MK2206)

Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Akt Inhibitor MK2206)14

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Akt Inhibitor MK2206)18Not reported11.829.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11.8
        upper Limit
        29.9
        value
        18
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
Overall Survival is defined as the time from registration to death. The distribution of survival will be estimated using the method of Kaplan-MeierEstimated using Kaplan-Meier methodology.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO
    id
    OG000
    title
    Treatment (Akt Inhibitor MK2206)
param Type
MEDIAN
population Description
Two patients were not eligible for this endpoint.
reporting Status
POSTED
time Frame
Time of study entry to death due to any cause, assessed up to 3 years from registration
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice